Glioblastom

Molecular reporters expose the allies of the brain tumor

Until recently, it was unclear how and why cancer cells adapt to their environment. A team led by Dr. Gaetano Gargiulo at MDC has now developed a technology that can be used to observe the molecular processes in living cells. The researchers present their results in the journal Cancer Discovery.

Glioblastoma is the most common malignant brain tumor in adults. Roughly five in every 100,000 people develop this type of cancer each year. The diagnosis amounts to a death sentence: Even after surgical resection followed by radiation and chemotherapy, the glioblastoma will kill the patient in a few months. This is because the tumor invariably returns after treatment, and in a more aggressive form than before.

Researchers investigating glioblastoma tissue always find immune cells inside the tumor. They have therefore long suspected that these cells strengthen the tumor, instead of fighting it. A team led by Dr. Gaetano Gargiulo at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) has now supplied direct evidence of this. ”We developed a new technology which allows us to visualize, on a molecular level, how the innate immune cells end up defending the tumor cells rather than body” says Gargiulo.

We developed a new technology which allows us to visualize, on a molecular level, how the innate immune cells end up defending the tumor cells rather than body.
Dr. Gaetano Gargiulo
Dr. Gaetano Gargiulo Head of Molecular Oncology Lab

The researchers generated/created molecular reporters that produce fluorescence in a cell if that cell is running complex programs, such as the kind that changes the cell identity. They have published their findings in the journal Cancer Discovery. The lead authors are Matthias Jürgen Schmitt, Carlos Company, and Yuliia Dramaretska – all doctoral students in Gargiulo’s Molecular Oncology Lab. The group collaborated with scientists at the Netherlands Cancer Institute, the Ludwig-Maximilians-Universität München, and the Spanish National Cancer Research Center.

Glioblastoma, previously known as glioblastoma multiforme, is a highly heterogeneous tumor. Drugs that are used successfully to treat some forms of bowel or breast cancer are powerless against glioblastoma. “This is firstly because most cancer drugs can’t get across the blood-brain barrier,” says Gargiulo. The blood-brain barrier is a complex set of cellular and molecular channels that regulates the access of substances to the brain tissue from circulating blood. It stops substances that don’t belong in the central nervous system from entering the brain via the capillaries. This is certainly one reason why only one drug could be approved so far for chemotherapy in glioblastoma patients and it eventually stops working pretty soon.

A basis for developing new medicines

A better understanding of the glioblastoma subtype identities, and of what triggers their changes, could be a guide for developing new and more effective therapies.
Matthias Schmitt
Matthias Schmitt Author of the publication in Cancer Discovery

Secondly, not all cancer cells are alike. The cells that give rise to glioblastoma are divided into multiple molecular subtypes. The composition changes over time. This is especially true with a recurrence – when a tumor returns after treatment. In these cases, the cells frequently transition to the most aggressive of the subtypes, which is deadlier than the others. “A better understanding of the glioblastoma subtype identities, and of what triggers their changes, could be a guide for developing new and more effective therapies,” says Matthias Schmitt.

This requires researchers to have an accurate understanding of the tumor’s biology – how it regulates its growth and how it interacts with nearby cells. Gargiulo and his team have now found the tool that allows them to comprehend these cellular processes. “Within the tumor cells’ genome, we’ve identified the regulators that program each subtype signature,” says Yuliia Dramaretska. “We then turned these short DNA segments into molecular reporters that fluoresce when the cells change.” They also show what triggered the change – e.g., immune cells, drugs, or ionizing radiation.

A versatile technology

“The molecular reporters can now help us work out how to stop the immune cells from making the tumor cells more aggressive,” says Gargiulo, explaining the future research plans. “Perhaps we can also encourage them to recruit other immune cells that will help them fight the tumor.”

The technology has already been patented, and the plan is to set up a spin-off that will further develop it. “It‘s not only useful with glioblastoma,” says Carlos Company. “It is potentially applicable to many other biological systems.” One very contemporary use that Gargiulo mentions is for research into the COVID-19. The MDC scientists plan to use it to develop tests that show, at a very early stage, whether the virus is attacking the lung tissue. They could investigate drug combinations to see whether these stop the pathogen from replicating in the cells and mount an anti-viral response. The method could also provide insights into how and why drugs work against COVID-19.

 

Further information

 

Download

"Bisher nur vermutet, jetzt dank des molekularen Reporters sichtbar gemacht: Wo menschliche Tumorzellen und Gehirnzellen einer Maus aufeinandertreffen, haben die Tumorzellen eine andere Identität als überall sonst (grün)." © AG Gargiulo, MDC

 

Literature

Matthias Jürgen Schmitt, Carlos Company, Yuliia Dramaretska et al (2020): Phenotypic mapping of pathological crosstalk between glioblastoma and innate immune cells by synthetic genetic tracing, DOI: 10.1158/2159-8290.CD-20-0219

 

Press contacts

Dr. Gaetano Gargiulo
Head of Molecular Oncology Lab
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
gaetano.gargiulo@mdc-berlin.de

Jana Ehrhardt-Joswig
Editor, Communications Department
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
jana.ehrhardt-joswig@mdc-berlin.de or presse@mdc-berlin.de

The Max Delbrück Center for Molecular Medicine (MDC)

The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) is one of the world’s leading biomedical research institutions. Max Delbrück, a Berlin native, was a Nobel laureate and one of the founders of molecular biology. At the MDC’s locations in Berlin-Buch and Mitte, researchers from some 60 countries analyze the human system – investigating the biological foundations of life from its most elementary building blocks to systems-wide mechanisms. By understanding what regulates or disrupts the dynamic equilibrium in a cell, an organ, or the entire body, we can prevent diseases, diagnose them earlier, and stop their progression with tailored therapies. Patients should benefit as soon as possible from basic research discoveries. The MDC therefore supports spin-off creation and participates in collaborative networks. It works in close partnership with Charité – Universitätsmedizin Berlin in the jointly run Experimental and Clinical Research Center (ECRC), the Berlin Institute of Health (BIH) at Charité, and the German Center for Cardiovascular Research (DZHK). Founded in 1992, the MDC today employs 1,600 people and is funded 90 percent by the German federal government and 10 percent by the State of Berlin.